Knipp, M; Karotki, A V; Chesnov, S; Natile, G; Sadler, P J; Brabec, V; Vasák, M (2007). Reaction of Zn7metallothionein with cis- and trans-[Pt(N-donor)2Cl2] anticancer complexes: trans-Pt(II) complexes retain their N-donor ligands. Journal of Medicinal Chemistry, 50(17):4075-4086.
Full text not available from this repository.
Intrinsic and acquired resistance are major drawbacks of platinum-based cancer therapy. The protein superfamily of cysteine- and ZnII-rich proteins, metallothioneins (MT), efficiently inactivate these antitumor drugs because of the strong reactivity of platinum compounds with S-donor molecules. In this study the reactions of human Zn7MT-2 with twelve cis/trans-[Pt(N-donor)2Cl2] compounds and [Pt(dien)Cl]Cl, including new generation drugs, were investigated and the products characterized. A comparison of reaction kinetics revealed that trans-PtII compounds react faster with Zn7MT-2 than cis-PtII compounds. The characterization of the products showed that while all ligands in cis-PtII compounds were replaced by cysteine thiolates, trans-PtII compounds retained their N-donor ligands, thus remaining in a potentially active form. These results provide an increased understanding of the role of MT in the acquired resistance to platinum-based anticancer drugs.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Functional Genomics Center Zurich|
08 University Research Priority Programs > Systems Biology / Functional Genomics
|DDC:||570 Life sciences; biology|
610 Medicine & health
|Date:||23 August 2007|
|Deposited On:||28 Dec 2009 07:27|
|Last Modified:||27 Nov 2013 16:22|
|Publisher:||American Chemical Society|
|Citations:||Web of Science®. Times Cited: 50|
Scopus®. Citation Count: 51
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page